Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance. Zhang Y, Xu Y, Xu J, Zhong H, et al. Cancer Sci 2025;116:753-763.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhang Y, Xu Y, Xu J, Zhong H, et al. Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance. Cancer Sci 2025;116:753-763.
PMID: 39741120